HOME >> MEDICINE >> NEWS
Anti-inflammatory drug's potentially deadly side effect found to be rare

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

The new study found no new cases of progressive multifocal leukoencephalopathy (PML) and confirmed the three previously identified cases of PML associated with use of the drug. One fatal and one nonfatal case of PML occurred in a trial using natalizumab as a multiple sclerosis treatment; a second fatality happened in a trial that used the drug to treat patients with Crohn's disease, an inflammatory bowel disorder.

"Our analysis suggests about one in every1,000 people who took natalizumab contracted this disease; however, there weren't enough patients exposed to the drug to allow us to precisely estimate the risk, which could be as low as one in 5,000 or as high as one in 300," says senior author David Clifford, M.D., the Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology at Washington University School of Medicine in St. Louis.

The results of the study, along with two separate studies of natalizumab's effectiveness as an MS treatment, are published in this week's issue of The New England Journal of Medicine.

The brand name of natalizumab, which was jointly developed by Biogen and Elan Pharmaceuticals, is Tysabri. The drug is a monoclonal antibody that binds to inflammatory immune T cells and prevents them from crossing membranes that protect the brain and the central nervous system. Prior to the studies that were halted last year, earlier studies showed a 66 percent reduction in the rate of relapses in MS patients treated with the natalizumab, which has to be injected on a monthly basis.

Clifford predicts that his group's report and the other studies of natalizumab will be important elements in "lively" discussions to be held by the Food and Drug Administration reg
'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
1-Mar-2006


Page: 1 2 3 4

Related medicine news :

1. Anti-inflammatory drug prevents liver cancer in at-risk liver patients
2. Anti-inflammatory drugs following hip replacement surgery could harm rather than help
3. Anti-inflammatory function of Alzheimers disease drugs revealed
4. A drugs brand name skews patient treatment choices
5. Chemical maps hint at drugs effects on schizophrenia
6. Study to test drugs potential to preserve insulin production in newly diagnosed type 1 diabetics
7. Trial demonstrates new drugs effectiveness against psoriasis
8. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
9. STAMP system can help professionals to identify potentially violent individuals
10. Women with breast cancer do not get potentially life-saving information, survey reveals
11. U-M study finds some prostate cancer patients potentially overtreated

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti inflammatory drug potentially deadly side effect found rare

(Date:4/1/2015)... BioPlus Specialty Pharmacy (BioPlus), ... released a new app to keep health care providers ... hepatitis C virus (HCV) infection. This ‘HCV Treatment Path’ ... the American Association for the Study of Liver Diseases ... direct-acting oral medications to treat HCV have been approved ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will be ... the benefits of the LANAP® treatment over traditional ... People who live in Howard County, and surrounding areas ... visit Dr. Stewart, a Maryland dentist, for a minimally ... protocol, which is a laser gum surgery procedure, Dr. ...
(Date:4/1/2015)... 2015 OSF Saint Paul Medical Center, ... , was welcomed into the Ministry April 1, 2015, ... Paul E. Showalter, vicar general of the Catholic Diocese ... culminated a nearly year-long transition process for the former ... Speakers for the morning ceremony included Sister Judith Ann ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , ... of the Department of Plastic Surgery at UT Southwestern ... reports of blindness resulting from the use of ... published their study, along with ideas for treatment and ... "We began to see increasing reports of blindness as ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
(Date:4/1/2015)... April 1, 2015   Advocates for Responsible Care ... health care professionals, patient advocates and human rights ... which will go live at 9:00 a.m. today. ... in Reach is a new campaign to limit rising ... families. Led by Advocates for Responsible Care, in partnership with ...
(Date:4/1/2015)... NEW YORK , April 1, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming HIMSS 2015 Conference. The conference ... Chicago , from April 12 through 16. In ... at their respective booths, AMC Health will share innovations ...
(Date:4/1/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... industry veteran, Erich Mohr , Ph.D., R.Psych., to ... Dr. Mohr has close to two decades of ... scientific officer, chief executive officer and board member, including ...
Breaking Medicine Technology:'Rx in Reach' Campaign Launches in Georgia 2'Rx in Reach' Campaign Launches in Georgia 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 3DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 4
Cached News: